Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK And SuperGen In Epigenetics Pact

by Ann M. Thayer
November 2, 2009 | A version of this story appeared in Volume 87, Issue 44

GlaxoSmithKline and SuperGen will work together to discover cancer therapies based on epigenetic, or gene expression, targets. Epigenetic processes, in which gene regulation is altered without changes to the underlying DNA, are believed to play a role in the development and progression of most cancers. GSK will pay SuperGen $5 million up front, including the purchase of $3 million in stock, and potentially up to $375 million in milestone payments. After SuperGen advances compounds to the early clinical proof-of-concept stage, GSK has the right to further develop and commercialize them.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.